Skip to Content

Yescarta FDA Approval History

FDA Approved: Yes (First approved October 18, 2017)
Brand name: Yescarta
Generic name: axicabtagene ciloleucel
Dosage form: Suspension for Intravenous Infusion
Previous Name: KTE-C19
Company: Kite Pharma, Inc.
Treatment for: Large B-Cell Lymphoma

Yescarta (axicabtagene ciloleucel) is a chimeric antigen receptor T cell (CAR T) therapy for the treatment of adults patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.

CAR T therapy involves the engineering of a patient's T cells to express a chimeric antigen receptor (CAR) to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias. The T cells are then redirected to kill the cancer cells. CAR T therapy is manufactured specifically for each individual patient and is considered a breakthrough in hematologic cancer treatment.

Development Timeline for Yescarta

Dec 11, 2017Kite Announces Data From ZUMA-3 Study of KTE-C19 in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia
Dec 10, 2017Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma
Oct 18, 2017Approval FDA Approves Yescarta (axicabtagene ciloleucel) CAR-T Cell Therapy to Treat Adults with Certain Types of Large B-Cell Lymphoma
May 26, 2017Kite Receives U.S. Food and Drug Administration Priority Review for Axicabtagene Ciloleucel
Mar 31, 2017Kite Completes Submission of U.S. Biologics License Application (BLA) for Axicabtagene Ciloleucel as the First CAR-T Therapy for the Treatment of Patients With Aggressive Non-Hodgkin Lymphoma (NHL)

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.